Financial Performance - The company's revenue for Q1 2025 was ¥295,757,022.22, representing a 5.05% increase compared to ¥281,550,999.26 in the same period last year[4] - Net profit attributable to shareholders decreased by 10.62% to ¥51,874,993.62 from ¥58,039,870.20 year-on-year[4] - Basic and diluted earnings per share both decreased by 7.14% to ¥0.13 from ¥0.14 year-on-year[4] - Total operating revenue for the current period reached ¥295,757,022.22, an increase of 5.4% compared to ¥281,550,999.26 in the previous period[20] - Net profit for the current period was ¥51,874,993.62, a decrease of 10.0% from ¥58,039,870.20 in the previous period[21] - Basic earnings per share for the current period was ¥0.13, down from ¥0.14 in the previous period[22] Cash Flow - The net cash flow from operating activities plummeted by 97.98% to ¥1,509,899.67, down from ¥74,921,798.44 in the previous year[4] - Cash inflow from operating activities totaled $417,923,048.16, an increase from $299,924,478.89 in the previous period, representing a growth of approximately 39.4%[24] - Cash outflow from operating activities was $416,413,148.49, up from $225,002,680.45, indicating a rise of about 85.1%[25] - Net cash flow from operating activities decreased to $1,509,899.67 from $74,921,798.44, reflecting a decline of approximately 98%[25] - Cash inflow from investment activities amounted to $620,943,757.30, compared to $379,495,840.28 in the prior period, marking an increase of about 63.7%[25] - Net cash flow from investment activities was -$112,938,114.65, an improvement from -$332,218,844.82, indicating a reduction in cash outflow by approximately 66%[25] - Cash inflow from financing activities was $8,500,000.00, with no previous inflow reported[25] - Net cash flow from financing activities was -$4,812,312.16, worsening from -$1,875,130.18 in the previous period[25] - The ending balance of cash and cash equivalents was $703,604,951.22, a decrease from $935,304,050.79[25] Assets and Liabilities - Total assets increased by 2.15% to ¥4,005,917,773.80 compared to ¥3,921,612,493.46 at the end of the previous year[4] - Total liabilities increased to ¥484,038,229.01, compared to ¥441,955,306.48 in the previous period, marking a rise of 9.3%[18] - The company's total equity reached ¥3,521,879,544.79, an increase from ¥3,479,657,186.98 in the previous period, reflecting a growth of 1.2%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,334, with the largest shareholder holding 45.74% of the shares[11] - The company has completed a share repurchase plan, acquiring 2,368,840 shares, which represents 0.5825% of the total share capital, with a total expenditure of RMB 61,568,589.91[14] - The highest transaction price during the share repurchase was RMB 29.72 per share, while the lowest was RMB 22.80 per share[14] - The company plans to use between RMB 50 million and RMB 100 million for share repurchase to support employee stock ownership plans[14] Expenses and Investments - Research and development expenses rose by 43.84% to ¥32,674,593.72 from ¥22,716,655.12 in the previous year, indicating a focus on innovation[10] - Total operating costs increased to ¥246,494,069.60, up 13.6% from ¥216,931,034.93 in the previous period[20] - Investment income surged by 195.63% to ¥1,560,436.03, up from ¥527,840.49, reflecting improved financial management[10] - The company experienced a 312.33% increase in taxes and surcharges, amounting to ¥3,928,808.21, due to increased tax liabilities[10] Strategic Initiatives - The company has initiated a "Quality Return Dual Improvement" action plan aimed at enhancing investor confidence and promoting sustainable development[13] - The company is focused on maintaining the interests of all shareholders, particularly small and medium-sized investors, as part of its strategic initiatives[13] - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[23] Other Financial Metrics - The company reported a total cash balance of RMB 1,220,372,277.91 as of March 31, 2025, down from RMB 1,252,273,385.93 at the beginning of the period, reflecting a decrease of approximately 2.54%[16] - The company's accounts receivable decreased to RMB 264,339,226.05 from RMB 344,626,321.14, indicating a decline of about 23.3%[16] - The company’s trading financial assets decreased to RMB 481,450,753.59 from RMB 491,733,204.65, a reduction of approximately 2.5%[16] - Other receivables increased significantly to RMB 102,460,141.31 from RMB 5,295,014.62, marking a substantial rise of over 1,837%[16] - The company’s prepayments decreased to RMB 10,611,293.21 from RMB 12,667,577.34, reflecting a decline of about 16.2%[16] Audit Status - The first quarter report for 2025 was not audited[27]
美好医疗(301363) - 2025 Q1 - 季度财报